Sales 2025 by Business Segment

Sales 2025 by Geography

Historical Breakdown of Revenue by Business Segments

Operating Income: Breakdown by Business Segment

Breakdown by Business Segment (EUR)
Fiscal Period: December 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

Life Sciences Tools and Services

          

Discovery and Preclinical Development

- - - 61Cr 53Cr

Gross Profit

- - - 10Cr 4.68Cr

EBITDA

- - - 1.27Cr -1.2Cr

D&A

- - - 7.72Cr 7.48Cr

Operating Income

- - - -13Cr -7.45Cr

Just - Evotec Biologics

- - - 19Cr 26Cr

Gross Profit

- - - 1.36Cr 6.74Cr

EBITDA

- - - 98.69L 5.32Cr

D&A

- - - 2.44Cr 2.47Cr

Operating Income

- - - -1.64Cr 1.83Cr

EVT Innovate

15Cr 20Cr 27Cr - -

Gross Profit

- - - - -

EBITDA

-1.75Cr -66.02L 10L - -

D&A

39.91L 50.87L 54.47L - -

Operating Income

-2.21Cr -1.17Cr -44.89L - -

EVT Execute

61Cr 74Cr 74Cr - -

Gross Profit

- - - - -

EBITDA

12Cr 11Cr 6.54Cr - -

D&A

6.36Cr 7.66Cr 8.75Cr - -

Operating Income

6.31Cr 3.25Cr -4.3Cr - -

Transition

- - - - -

Intersegment Elimination

-14Cr -19Cr -22Cr -12.08L -5L

Gross Profit

- - - -9L -17T

Operating Income

- - - - -

Geographical Revenue Distribution History

Geographical breakdown of sales (EUR)
Fiscal Period: December 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

USA

- - 46Cr 45Cr 43Cr

Total Assets

- - 22Cr 26Cr 22Cr

Switzerland

- - 6.49Cr 11Cr 16Cr

Total Assets

- - - - -

Total Assets

- - 26.34L - -

Total Assets

- - - - -

Total Assets

- - - - -

Rest of the World

- - 9.52Cr 8.23Cr 7.71Cr

United Kingdom

- - 8.64Cr 9.25Cr 6.17Cr

Total Assets

- - 22Cr 21Cr 18Cr

Germany

- - 3.41Cr 3.29Cr 2.53Cr

Total Assets

- - 15Cr 15Cr 19Cr

France

- - 3.2Cr 1.99Cr 1.99Cr

Total Assets

- - 34Cr 33Cr 8.97Cr

Total Assets

- - 26Cr 24Cr 23Cr

Unallocated

- - - 1.44Cr 1.13Cr

Europe

- - - - -
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!